BOCA RATON, Fla., Jan. 7 /PRNewswire/ -- Jacobson Resonance Enterprises Inc.
(OTC Bulletin Board: JRSE) announced today a year-long study performed at
Cornell University Medical College has demonstrated that sciatic nerves of
mice exposed to the Jacobson Resonator's low-level magnetic fields resulted in
nerve growth and regeneration including the myelin sheath.
A team of Cornell researchers led by Dr. Brij Saxena, used the Jacobson
Resonator in applying low-level magnetic fields to mice sciatic nerves in
vitro. The experiment found exposure to the unit's low-level magnetic fields
triggered growth and regeneration of nerve sections in culture medium. They
also found that those nerves that were not exposed to the magnetic fields
experienced nerve degeneration.
"At the end of the year, we found included in the new growth was the myelin
sheath, a structure responsible for normal nerve conduction of impulses," said
Dr. Saxena. These findings are especially important because the myelin sheath
is the one part of the nerve that is commonly lost in neurological diseases
like multiple sclerosis."
"The results serve as a milestone from which to view the possibility to help
millions of people suffering from neurological diseases," said Dr. Jerry
Jacobson, inventor of the technology and one of the world's leading
researchers in the magneto therapy field. "I've always believed this
technology could be used to regenerate nerve cells, and this study brings us
one step closer to our ultimate goal, the demonstration of clinical efficacy,"
he added.
Jacobson Resonance Enterprises Inc., a leader in the emerging field of bio-
electromagnetic resonance, is conducting double-blind randomized clinical
studies at four sites in seeking FDA approval in the U.S. The company has
applied for a Certificate of Conformance, commonly known as a CE-Mark, which
allows manufacturing and distribution of its proprietary bio-electromagnetic
medical equipment in the European Common Market for treatment and amelioration
of pain. The CE-Mark is the European equivalent to the FDA marketing approval
in the U.S.
Forward-looking statements in this release are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are subject to certain risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission.
SOURCE Jacobson Resonance Enterprises Inc.
CO: Jacobson Resonance Enterprises Inc.; Cornell University Medical College
ST: Florida, New York
IN: MTC
SU:
01/07/99 11:34 EST http://www.prnewswire.com